title: Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
abstract: We report the recent isolation of Cryptococcus laurentii from the feces of a patient with Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplant (HSCT). The organism was identified using microscopic morphology, cultural characteristics, and biochemical tests including sugar assimilation. Minimum inhibitory concentration of various antifungals was determined by microbroth dilution method. The recovery of pure culture of C. laurentii from stool culture, and the patient's response to treatment with voriconazole support its potential etiological role. To the best of our knowledge, we report the first case of diarrhea caused by C. laurentii in an HSCT recipient.
authors.affiliation: Department of Microbiology, ACTREC-Tata Memorial Centre, Mumbai, India.
authors.forename: Vivek
authors.initials: V
authors.lastname: Bhat
authors.affiliation: Department of Microbiology, ACTREC-Tata Memorial Centre, Mumbai, India.
authors.forename: Hemant
authors.initials: H
authors.lastname: Vira
authors.affiliation: Medical Oncology, Bone Marrow Transplant Unit, ACTREC-Tata Memorial Centre, Mumbai, India.
authors.forename: Navin
authors.initials: N
authors.lastname: Khattry
authors.affiliation: Medical Oncology, Bone Marrow Transplant Unit, ACTREC-Tata Memorial Centre, Mumbai, India.
authors.forename: Manoj
authors.initials: M
authors.lastname: Toshniwal
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000328:Adult; D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D003453:Cryptococcosis / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*; D003454:Cryptococcus / Q000302:isolation & purification*; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003967:Diarrhea / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology; D015725:Fluconazole / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000601:surgery*; D006801:Humans; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014182:Transplantation, Autologous / Q000009:adverse effects; D065819:Voriconazole / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D003561:Cytarabine; D005047:Etoposide; D015725:Fluconazole; D002097:C-Reactive Protein; D065819:Voriconazole; D008558:Melphalan; D002330:Carmustine
keywords: 
  BMT
  ; 
  C. laurentii
  ; 
  Cryptococcus
  ; diarrhea; infection